Muscarinic receptor subtypes coupled to generation of different second messengers in isolated tracheal smooth muscle cells.
1. Activation of muscarinic receptor subtypes leads to contraction, an increase in the accumulation of inositol phosphates (IPs) and a decrease in adenosine 3': 5'-cyclic monophosphate (cyclic AMP) synthesis in tracheal smooth muscle. The concentrations of carbachol that produced a half-maximal effect (EC50) in inhibition of cyclic AMP generation, stimulation of IPs formation and contraction were 15 nM, 2.0 microM and 0.17 microM, respectively. 2. Pirenzepine, a selective M1 antagonist, displayed a low affinity for antagonizing cyclic AMP inhibition, IPs formation and contraction induced by carbachol (pKB = 6.8, 7.0, and 7.1, respectively). 3. Methoctramine, a cardioselective M2 antagonist, blocked cyclic AMP inhibition with a high affinity (pKB = 7.5), while it antagonized IPs formation and contraction with a low affinity (pKB = 6.2 and 6.1, respectively). 4. 4-Diphenylacetoxy-N-methylpiperidine (4-DAMP), a selective smooth muscle M3 antagonist, possessed a high affinity in blocking IPs formation (pKB = 8.8) and contraction (pKB = 9.2) as well as a low affinity for antagonism of cyclic AMP inhibition (pKB = 8.1). 5. In conclusion, we have demonstrated that M2 and M3 receptor subtypes are coupled to different effector systems in tracheal smooth muscle. An M1 receptor subtype is not involved in the generation of the second messengers examined. Inhibition of cyclic AMP formation may be coupled to the M2 receptor subtype. The accumulation of IPs and presumably IP-induced Ca2+ release may function as the transducing mechanism for cholinergic contraction of tracheal smooth muscle through the activation of M3 receptors.
Yang
C M
CM
Department of Pharmacology, Chang Gung Medical College, Tao-Yuan, Taiwan.
Chou
S P
SP
Sung
T C
TC
D000067956:Adenylyl Cyclase Inhibitors; D000818:Animals; D001667:Binding, Competitive / Q000187:drug effects; D002217:Carbachol / Q000494:pharmacology; D000242:Cyclic AMP / Q000096:biosynthesis; D004285:Dogs; D066298:In Vitro Techniques; D009130:Muscle, Smooth / Q000166:cytology / Q000187:drug effects*; D010276:Parasympatholytics / Q000494:pharmacology; D010716:Phosphatidylinositols / Q000494:pharmacology; D011976:Receptors, Muscarinic / Q000187:drug effects*; D015290:Second Messenger Systems / Q000187:drug effects*; D015398:Signal Transduction / Q000187:drug effects; D014132:Trachea / Q000166:cytology / Q000187:drug effects
D000067956:Adenylyl Cyclase Inhibitors; D010276:Parasympatholytics; D010716:Phosphatidylinositols; D011976:Receptors, Muscarinic; D002217:Carbachol; D000242:Cyclic AMP